LOS ANGELES, May 19, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has retained The Emmes Group to assist the Company in business development, market research and analysis, and strategic planning. With offices in Boston and San Francisco, The Emmes Group is a leading strategic advisory firm serving the healthcare and technology industries.
"The Emmes Group will play an important role as we execute on the previously announced expansion of our therapeutic strategy to include autologous cell therapies to treat various cancers," said Anthony J. Cataldo, President and Chief Executive Officer of Genesis Biopharma. "We have made significant progress in recent weeks in establishing a therapeutic development program based on autologous cell therapy, and The Emmes Group has the expertise and relationships to help us advance through the clinical and regulatory process, and ultimately into a commercial phase."
Martin Schroeder, Executive Vice President and Managing Director of The Emmes Group, stated, "Autologous cell therapy, which utilizes cells from a patient's own immune system to treat cancer, is one of the most promising areas of oncology research and treatment. We look forward to assisting Genesis Biopharma and its world-class Scientific and Medical Advisory Board in bringing together the necessary intellectual property and technology assets, along with the scientific and manufacturing expertise, to support its autologous cell therapy program."
About The Emmes Group
The Emmes Group is a strategy consulting and market research organization supporting firms engaged in the technology and healthcare industries. Its partners have more than 50 years of combined experience. The firm works in partnership with its clients to increase profits and build lasting economic value. The firm's expertise spans a number of key areas, including: Strategy Consulting, Partnerships, Mergers & Acquisitions, Strategic Marketing, Market Research & Modeling, Business Development, Technology Licensing, Corporate Financing and, Venture Capital Due Diligence. For additional information, please visit http://www.emmesgroup.com.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.
Forward-Looking Statements
The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Genesis Biopharma, Inc.
Advertisement
"The Emmes Group will play an important role as we execute on the previously announced expansion of our therapeutic strategy to include autologous cell therapies to treat various cancers," said Anthony J. Cataldo, President and Chief Executive Officer of Genesis Biopharma. "We have made significant progress in recent weeks in establishing a therapeutic development program based on autologous cell therapy, and The Emmes Group has the expertise and relationships to help us advance through the clinical and regulatory process, and ultimately into a commercial phase."
Advertisement
Martin Schroeder, Executive Vice President and Managing Director of The Emmes Group, stated, "Autologous cell therapy, which utilizes cells from a patient's own immune system to treat cancer, is one of the most promising areas of oncology research and treatment. We look forward to assisting Genesis Biopharma and its world-class Scientific and Medical Advisory Board in bringing together the necessary intellectual property and technology assets, along with the scientific and manufacturing expertise, to support its autologous cell therapy program."
About The Emmes Group
The Emmes Group is a strategy consulting and market research organization supporting firms engaged in the technology and healthcare industries. Its partners have more than 50 years of combined experience. The firm works in partnership with its clients to increase profits and build lasting economic value. The firm's expertise spans a number of key areas, including: Strategy Consulting, Partnerships, Mergers & Acquisitions, Strategic Marketing, Market Research & Modeling, Business Development, Technology Licensing, Corporate Financing and, Venture Capital Due Diligence. For additional information, please visit http://www.emmesgroup.com.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.
Forward-Looking Statements
The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Genesis Biopharma, Inc.
